



This is a repository copy of *Fabrication of biodegradable synthetic vascular networks and their use as a model of angiogenesis*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/101405/>

Version: Accepted Version

---

**Article:**

Dew, L., English, W.R. [orcid.org/0000-0003-3024-2441](http://orcid.org/0000-0003-3024-2441), Ortega, I. et al. (2 more authors) (2016) Fabrication of biodegradable synthetic vascular networks and their use as a model of angiogenesis. *Cells Tissues Organs*. 446644. ISSN 1422-6405

<https://doi.org/10.1159/000446644>

---

This is the peer-reviewed but unedited manuscript version of the following article: Dew, L., English, W.R. , Ortega, I., Claeysens, F. and MacNeil, S. (2016) Fabrication of biodegradable synthetic vascular networks and their use as a model of angiogenesis. *Cells Tissues Organs*. ISSN 1422-6405. The final, published version is available at <http://www.karger.com/10.1159/000446644>

**Reuse**

Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

1 Fabrication of biodegradable synthetic vascular networks and their use as  
2 a model of angiogenesis

3

4 Lindsey Dew, William R English<sup>a</sup>, Ilida Ortega<sup>b</sup>, Frederik Claeyssens\*, Sheila  
5 MacNeil\*

6

7 Kroto Research Institute, University of Sheffield, Broad Lane, Sheffield S3 7HQ, UK.

8 <sup>a</sup>Tumour Microcirculation Group, Department of Oncology, School of Medicine, The

9 University of Sheffield, Sheffield, S10 2RX, UK. <sup>b</sup>School of Clinical Dentistry,

10 Claremont Crescent, University of Sheffield, Sheffield S10 2TA, UK.

11

12

13 Short Title: Synthetic vascular nets as 3D models of angiogenesis

14

15 Keywords: Angiogenesis, Electrospinning, Robocasting, Tissue Engineering,

16 Regenerative Medicine.

17

18

19

20

21

22

23 \*Corresponding Author:

24 Kroto Research Institute, University of Sheffield, Broad Lane, Sheffield S3 7HQ, UK. Dr Frederik Claeyssens

25 (Email: [f.claeyssens@sheffield.ac.uk](mailto:f.claeyssens@sheffield.ac.uk), Tel: +44 (0) 114 222 5513, Fax: +44 (0) 114 222 5943) & Professor Sheila

26 MacNeil (Email: [s.macneil@sheffield.ac.uk](mailto:s.macneil@sheffield.ac.uk), Tel: +44 (0) 114 222 5995, Fax: +44 (0) 114 222 5943)

27 **Abstract**

28

29 One of the greatest challenges currently faced in tissue engineering is the  
30 incorporation of vascular networks within tissue-engineered constructs. The aim of  
31 this study was to develop a technique for producing a perfusable, three-dimensional  
32 cell friendly model of vascular structures that could be used to study the factors  
33 affecting angiogenesis and vascular biology in engineered systems in more detail.  
34 Initially, biodegradable synthetic pseudo-vascular networks were produced via the  
35 combination of robocasting and electrospinning techniques. The internal surfaces of  
36 the vascular channels were then recellularized with human dermal microvascular  
37 endothelial cells (HDMECs) with and without the presence of human dermal  
38 fibroblasts (HDFs) on the outer surface of the scaffold. After 7 days in culture,  
39 channels that had been reseeded with HDMECs alone, demonstrated irregular cell  
40 coverage. However when using a co-culture of HDMECs inside and HDFs outside the  
41 vascular channels, coverage was found to be continuous throughout the internal  
42 channel. Using this cell combination, collagen gels loaded with vascular endothelial  
43 growth factor were deposited onto the outer surface of the scaffold and cultured for a  
44 further 7 days after which endothelial cell (EC) outgrowth from within the channels  
45 into the collagen gel was observed showing the engineered vasculature maintains its  
46 capacity for angiogenesis. Furthermore the HDMECs appeared to have formed  
47 perfusable tubules within the gel. These results show promising steps towards the  
48 development of an *in vitro* platform upon which to study angiogenesis and vascular  
49 biology in a tissue-engineering context.

50

## 51 **Introduction**

52 There has been significant progress in the field of tissue engineering over recent  
53 years, however one of the current obstacles blocking major clinical translation is the  
54 production of thick ( $\geq 2$  mm), complex tissues due to the lack of rapid  
55 neovascularization of the constructs [Griffith et al., 2005]. Blood vessel formation is  
56 tightly regulated and relies on the chronologically precise adjustment of vessel  
57 growth, maturation and suppression of EC growth - all of which are controlled by a  
58 large number of factors that influence each other [Carmeliet and Jain, 2011]. To  
59 induce vascularization within tissue engineered (TE) substitutes these same processes  
60 need to occur and it is therefore not surprising that this remains a challenge in the  
61 tissue-engineering field.

62 The most promising approaches to circumvent slow revascularization of tissue  
63 engineered constructs have historically used the body as an *in vivo* bioreactor making  
64 use of the omentum and in some case arteriovenous shunts. For example Baumert et  
65 al 2007 and Saxena et al, 2010 used the omentum and the body as an *in vivo*  
66 bioreactor for tissue engineering of bladder and cardiac tissue respectively. Baumert  
67 et al used pig urothelial and smooth muscle cells seeded into sphere shaped small  
68 intestinal submucosa (SIS) matrix grafts and after 3 weeks, transferred into the  
69 omentum in the pig. Three weeks later at harvest, these were found to be highly  
70 vascularised and the authors concluded that the omentum permitted the *in vivo*  
71 maturation of these seeded scaffolds with the development of a dense vasculature  
72 which they anticipate to prevent fibrosis and loss of contractility. Saxena et al  
73 implanted their tissue engineered constructs - ovine oesophageal epithelial cells  
74 implanted on collagen sheets pre-seeded with fibroblasts to form a rudimentary

75 tubularised oesophagus into the sheep omentum and demonstrated vascular coverage  
76 and ingrowth into the periphery of the construct.

77

78 An alternative approach is that of using an arteriovenous shunt. Burla et al 2005  
79 achieved vascularisation for neonatal cardiac myocytes placed in silicone chambers  
80 close to a vascular pedicle. In 2006 Kneser et al used an arteriovenous loop in a rat  
81 model to overcome the problem of engineering larger volume bone tissues. This  
82 approach of using an AV shunt was considered in a review of the challenges of  
83 angiogenesis and tissue engineering by Laschke et al 2006. These authors concluded  
84 however that future directions should focus on the creation of microvascular networks  
85 within 3D tissue constructs *in vitro* prior to implantation. We have also recently  
86 reviewed this area (Dew et al., 2015 and conclude that progress remains slow in  
87 neovascularisation of tissue engineered constructs because there are very few systems  
88 which allow one to study perfusion conditions, the cell type and scaffold architecture  
89 – all of which are important for neovascularization. We suggest it is therefore  
90 important to take a step back and understand how these factors work together to  
91 promote angiogenesis in order to advance this crucial area.

92 Clinically the study of angiogenesis has increased rapidly over the last 40 years as a  
93 result of its major role in a number of pathologies including cancer, rheumatoid  
94 arthritis and retinopathies to name but a few [Carmeliet, 2000]. Assays have been  
95 developed in an attempt to study the process. Ideally these would enable the  
96 assessment of multiple factors, providing reliable and reproducible results directly  
97 relating to those found in the clinic [Staton et al., 2009]. From the observations  
98 gleaned from tissue engineering strategies this would include the combination of a  
99 relevant vascular architecture, the ability to incorporate the relevant cell combinations

100 along with flow conditions and appropriate extracellular matrix (ECM) components.  
101 There is currently no single 'gold standard' assay that provides a useful platform to  
102 incorporate all of these elements in an *in vitro* setting.  
103 We have developed a novel 4-step technique to produce an *in vitro* angiogenesis  
104 model via the combination of electrospinning and robocasting methods used widely in  
105 the tissue-engineering field [Ortega et al., 2015]. Using the combination of these two  
106 approaches offers a range of advantages in the design of angiogenesis assays. For  
107 instance, the use of robocasting allows for the tuning of the vascular network  
108 geometry in terms of size, thickness and morphology enabling bespoke designs to be  
109 tested rapidly and scaled-up easily where necessary. The use of electrospun fibres  
110 provides high levels of porosity and surface area to enable diffusion and facilitate cell  
111 attachment, respectively [Ashammakhi et al., 2008]. In addition electrospinning also  
112 offers the ability to easily spin different polymers allowing for the control of  
113 degradation times [Blackwood et al., 2008] and mechanical properties whilst enabling  
114 the combination of different membrane combinations, as recently reported by our  
115 group [Bye et al., 2013]. Synthetic pseudovascular networks produced via this  
116 methodology provide a surface that supports EC adhesion [Ellis-Behnke et al., 2006;  
117 Beachley and Wen, 2010; Bye et al., 2013] and could provide the ability to test a  
118 range of angiogenic growth factors, combine multiple cell combinations and study the  
119 effects of perfusion through interconnected afferent and efferent channels. In this  
120 study we firstly describe the recellularization of such scaffolds using both HDMECs  
121 and HDFs in different combinations. We then describe the use of these scaffolds to  
122 observe the outgrowth of 3D tubular structures into a Vascular Endothelial Growth  
123 Factor (VEGF) loaded collagen gel.

124

125

126 **Materials and Methods**

127 *Production of synthetic pseudovascular nets.* Synthetic pseudovascular nets were  
128 produced using a 4 step technique using a combination of electrospinning and  
129 robocasting as previously published [Ortega et al., 2015]. Briefly, electrospun mats  
130 were produced by dissolving medical grade poly(3-hydroxybutyrate-co-3-  
131 hydroxyvalerate) (PHBV; Goodfellow) in a mixture of dichloromethane (DCM) and  
132 methanol. An optimal concentration of 10% w//w of PHBV (containing 10% w//w of  
133 methanol) was prepared and electrospun. Alginate was robocast onto the PHBV  
134 electrospun mat with the purpose of acting as a sacrificial template. An alginate paste  
135 was placed inside a syringe barrel attached to a dispensing system (Ultra 2800, EFD  
136 Inc., East Province, USA) whilst a 3D printer (RepRap Mendel, Oldbury on Severn,  
137 UK) was used to hold the dispensing arm and print the alginate. The electrospinning  
138 process was then repeated to cover the alginate sacrificial template with a nanofibrous  
139 PHBV layer. To remove the alginate and achieve the creation of a hollow network  
140 between the two electrospun mats, the scaffolds were submerged in 0.5 M  
141 ethylenediaminetetraacetic acid (EDTA) solution overnight on a gel-shaker set to 70  
142 rpm.

143 The overall dimensions of these nets as shown in Fig 1 were 2x4cm with tubes that  
144 were approximately 0.5 mm wide with a flat bottom and curved ceiling with a height  
145 of 0.15 mm (please see [Ortega et al., 2015] for detailed structures). The hexagonal  
146 section of the scaffold measured approximately 5x7.5mm at the widest points.

147

148 *Cells and cell culture* Proliferating HDMECs from juvenile foreskin (Promocell,  
149 Heidelberg, Germany) were grown in gelatin coated (0.1% (w/v) pig skin gelatin in

150 PBS) T25 tissue culture flasks. Cells were grown in EC growth medium MV  
151 containing 0.05ml/ml FCS, 0.004 ml/ml EC growth supplement, 10ng/ml epidermal  
152 growth factor (recombinant human), 90 µg/ml heparin, 1 µg/ml hydrocortisone, 100  
153 U/ml penicillin, 0.1 mg/ml streptomycin and 0.25 µg/ml amphotericin B. Media was  
154 replenished every 2-3 days. HDMECs were passaged when they reached  
155 approximately 80% confluence, split using a ratio of 1:3 and were used at passage 5  
156 in this study. HDFs were cultured from skin samples taken from consenting patients  
157 undergoing elective abdominoplasty or breast reduction surgery, as described  
158 previously [Bye et al., 2014] and used under the requirements stipulated by Research  
159 Tissue Bank Licence 12179. HDFs were cultured in DMEM supplemented with FCS  
160 (10% v/v), streptomycin (0.1 mg/ml), penicillin (100 IU/ml) and amphotericin B (0.5  
161 g/ml) and used between passage 6-8.

162

163 *Endothelialization of synthetic pseudovascular nets.* Prior to cell culture, scaffolds  
164 were sterilized by immersion into 70% ethanol (v/v in distilled water) for 30 minutes,  
165 followed by washing with sterile PBS. Scaffolds were then cannulated with a 24G  
166 cannula (BD Insite<sup>®</sup>) under a dissection microscope (Wild Heerbrugg M3Z). In this  
167 study, varying cell combinations were seeded onto and within the synthetic scaffolds.  
168 These included; HDMECs seeded into the channels, a combination of HDMECs and  
169 HDFs seeded within the channels and finally HDMECs seeded within the channels  
170 and HDFs seeded on the outside surface of the channels. To ensure cells attached  
171 uniformly to the artificial channels seeding was performed using a two-stage process.  
172 First,  $0.5 \times 10^6$  HDMECs (per scaffold) were resuspended in 0.25ml of EC growth  
173 medium MV. Using a 1ml syringe the cell suspension was injected into the scaffold  
174 through the cannula, submerged in media and kept overnight in an incubator at 37 °C

175 and 5% CO<sub>2</sub>. The constructs were then turned over and a second suspension of 0.5 ×  
176 10<sup>6</sup> HDMECs was seeded and left overnight. For the introduction of HDFs into the  
177 channels, HDMECs were firstly allowed to attach to the scaffolds for a minimum of 3  
178 hours before injecting 0.5 × 10<sup>6</sup> HDFs and repeating this process following the second  
179 injection of HDMECs. For the introduction of HDFs onto the outside surface of the  
180 channels 0.5 × 10<sup>6</sup> HDFs were pipetted over the outer surface of the scaffolds  
181 immediately after the seeding of the HDMECs. The scaffolds were placed in an  
182 incubator for up to 2 hours at 37 °C and 5% CO<sub>2</sub> without being submerged in media  
183 to allow attachment of the HDFs. The scaffolds were then subsequently submerged in  
184 media overnight before repeating the process.

185

186 *Outgrowth of endothelial cells from biodegradable scaffolds into an extracellular*  
187 *matrix.* Scaffolds that had been recellularized and cultured at 37°C and 5% CO<sub>2</sub> for 7  
188 days were taken and the channels were pierced with a sterile 21G hypodermic needle  
189 (Terumo, MediSupplies, UK) to introduce small holes into the scaffold to allow cell  
190 migration out of the scaffold. Collagen gels (2 mg/ml) were prepared by adding 200  
191 µl rat tail collagen type I (3 mg/ml, Gibco, Life technologies, UK) to 100 µl of  
192 concentrated MEM solution (Gibco, Life Technologies, UK) and vascular endothelial  
193 growth factor (VEGF) to a final concentration of 10 ng/ml. The collagen solution  
194 (~50 µl) was then pipetted into the wells formed by the channels and allowed to set at  
195 37°C for 15 min. The scaffolds were then submerged in media and cultured for a  
196 further 7 days, changing the media every 3 days.

197

198 *Immunohistochemistry* Samples were fixed for 2 hours in 4% paraformaldehyde  
199 (PFA) w/v in HBSS with Ca<sup>2+</sup> and Mg<sup>2+</sup> before dehydrating using graded alcohol

200 washes and embedding in paraffin wax. 6  $\mu\text{m}$  sections were cut and mounted on  
201 slides and stained with Hematoxylin and Eosin (H&E) (Sigma Aldrich).

202

203 *Immunofluorescence staining.* Immunofluorescence staining was performed as  
204 described previously [Correa de Sampaio et al., 2012]. Briefly, samples were fixed in  
205 4% PFA (w/v) in HBSS with  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$  for 30 minutes. Samples were then  
206 quenched with 100 mM glycine, washed once with PBS and then blocked for 1 h with  
207 1% (w/v) bovine serum albumin (BSA) in PBS at room temperature (RT). Separate  
208 samples were then incubated with mouse monoclonal anti-human CD31 (1:20 in 1%  
209 (w/v) BSA, Dako, UK) and mouse monoclonal anti-human VE cadherin (CD144)  
210 (1:50 in 1% (w/v) BSA, BD Biosciences) at RT overnight.. The scaffolds were  
211 subsequently washed for 2 h in 1% BSA (w/v) in PBS with 0.1% Tween (v/v),  
212 followed by incubation with Alexa Fluor™ 546 nm goat anti-mouse secondary  
213 antibody (1:200 in 1% (w/v) BSA) (Life technologies) for 2 h at RT before  
214 counterstaining with the nuclear stain DAPI (1:1000 in 1% (w/v) BSA). Finally the  
215 scaffolds were washed with 1% BSA (w/v) in PBS with 1% Tween (v/v) for at least 8  
216 h, after which the samples were imaged using a Zeiss LSM 510 confocal microscope  
217 (Zeiss, UK) to observe cellular organization.

218

219 *Perfusion with FITC-lectin* To visualize potential vessel formation, the scaffolds were  
220 perfused with 100  $\mu\text{l}$  of FITC labelled tomato lectin (Vector Laboratories) at a rate of  
221 40  $\mu\text{l}/\text{min}$ , controlled using a syringe pump (Genie Plus, Kent Scientific, Connecticut,  
222 USA).The scaffolds were then fixed in 4% PFA (w/v) in HBSS with  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$   
223 for 30 minutes and subsequently immunostained for CD31 as described above.

224

225

## 226 **Results**

227 *The formation of a continuous endothelial cell monolayer within the pseudovascular*  
228 *net lumen requires the support of fibroblasts*

229 In order for the electrospun pseudovascular net ( shown in Fig 1A) to act as a model  
230 vascular structure that can support neovascularization within biological structures,  
231 optimization of seeding and growth of an endothelial monolayer within the scaffold  
232 lumen was performed. Initially HDMEC were injected ( by perfusing the nets by  
233 inserting a syringe as shown in Fig 1B ) at high density within the lumen alone and  
234 allowed to adhere to the upper and lower surfaces. After 7 days culture cell coverage  
235 was investigated using hematoxylin and eosin staining of the pseudovascular net in  
236 cross-section (Fig 2). Although HDMEC could be detected, coverage was not  
237 continuous (Fig. 2 A –C). Mesenchymal cells, including pericytes and fibroblasts,  
238 have been shown to support endothelial function in *in vitro* models, mimicking  
239 perivascular cells [Kirkpatrick et al., 2011]. To determine if HDFs can augment  
240 HDMEC adhesion and survival within the pseudovascular net, HDFs were first  
241 seeded within the lumen with the HDMECs as in other vascular models this can result  
242 in a self-organising system replicating endothelial-pericyte architecture [Kunz-  
243 Schughart et al., 2006; Hurley et al., 2010]. This resulted in continuous cellular  
244 coverage of the inside of the lumen (Fig. 2 D-F). As some of the signalling pathways  
245 known to regulate endothelial barrier function are also soluble growth factors, we also  
246 seeded HDFs on the outside of the pseudovascular net and HDMECs on the inside of  
247 the lumen, physically separating the cells. On H&E staining, increased cell coverage  
248 of the lumen was seen, although this did not appear as continuous as the seeding both  
249 HDMECs and HDFs within the lumen (Fig 2 G-I).

250 To further characterize the EC coverage within the lumen of the pseudovascular net,  
251 the net was sectioned to reveal the upper curved surface and the lower flat surface  
252 before staining with CD31 and DAPI and confocal imaging. In nets seeded with  
253 HDMECs alone, CD31 staining lacked continuity and the ECs had a rounded  
254 appearance, with little to no evidence of CD31 at cell-cell junctions, especially on the  
255 curved surface (Fig 3 A-B). Although H&E staining showed a continuous cell layer  
256 with both HDFs and HDMECs were seeded within the lumen, the CD31 staining did  
257 not show continuous endothelial coverage. However, unlike surfaces with ECs alone,  
258 patches of confluent ECs were observed with discernable cell-cell junction staining of  
259 CD31 that appeared to be partially detracted from the HDFs cells on the  
260 pseudovascular net, suggesting poor adhesion (Fig 3 C-D). In contrast, the  
261 combination of HDFs on the external surface and HDMECs on the internal surface  
262 generated a continuous endothelial monolayer with a characteristic ‘cobblestone’  
263 appearance and clear cell-cell junction staining of CD31, particularly on the curved  
264 surface (Fig 3 E-F). Furthermore, staining for the endothelial adherens junction  
265 protein VE-Cadherin confirmed the establishment of a confluent monolayer on the  
266 inside of the lumen when HDFs were cultured on the outside (Fig 4 A-B).

267

268 *Endothelial cells maintain the capacity to migrate out of the pseudovascular net to*  
269 *form new perfusable vascular structures within a biological matrix*

270 After establishing the HDMECs could form a continuous monolayer of cell within the  
271 lumen of the pseudovascular net, we next aimed to determine if these had the  
272 capacity to form new vascular structures within a biological matrix, as this would be  
273 required if the artificial vascular structure is to have the ability to integrate with  
274 engineered tissues or biological material in the future. Initial studies indicated that

275 HDMECs would not be able degrade the electrospun mat or invade through it in a  
276 timely manner for this to occur. Accordingly, the pseudovascular net was punctured  
277 providing discreet exit points for the HDMECs. The well-shaped region within the  
278 net's hexagon pattern was then filled with collagen-I gel containing VEGF to promote  
279 migration of the ECs from within the net into the gel (Fig 5A). After 7 days of culture  
280 a CD31 positive network was found extending throughout this collagen-I gel with the  
281 appearance of a crude vascular network (Fig 5B) surrounded by HDFs that had also  
282 migrated into the gel.

283 We then aimed to determine if the new vasculature could be perfused via the  
284 pseudovascular net by injection of FITC-Lectin, commonly used *in vivo* to investigate  
285 vascular function [Thurston et al., 1998; Ezaki et al., 2001; Mazzetti et al., 2004].  
286 Confocal imaging showed significant overlap between CD31 and FITC-Lectin  
287 indicating perfusion had occurred (Fig 5C). It is important to note that these  
288 experiments were repeated 5 times with at least 6 replicates per experiment and vessel  
289 formation was found in around 50% of samples.

290 These structures generated in the pseudovascular nets were apparently random and  
291 looked more like large sinusoids/lymphoid structures than blood vessels. In width  
292 they ranged from 10 $\mu$ m up to structures which at their widest were closer to 80 $\mu$ m.  
293 There was no obvious pattern. They extended partially throughout the collagen  
294 /VEGF gel (spanning approximately 1cm from the peripheral vascular channel in all  
295 directions) within the 7 days of culture.

296

## 297 **Discussion**

298 The aim of this study was to develop a controllable 3D *in vitro* model of vascular  
299 structures to study the factors affecting angiogenesis and vascular biology. The

300 ultimate aim of this work is to translate the use of such vascular networks to the clinic  
301 in order to assist in the “take” of TE materials that lack intrinsic vasculature.

302 For many years it has been recognized that while it is possible to produce human 3D  
303 TE constructs in the laboratory, unless they are very thin epithelial structures they can  
304 be lost upon transplantation due to delays in neovascularization [Griffith et al., 2005].  
305 Introducing a vascular network into a TE construct is a major challenge which only a  
306 few groups are tackling. In an attempt to understand the fundamental principles  
307 behind the induction of angiogenesis, development of 3D models investigating the  
308 interactions between different cell types have progressed [Montesano et al. 1993;  
309 Donovan et al., 2001; Santos et al., 2008]. Other studies have looked at the influence  
310 of fluid flow on EC survival and sprouting [Moll et al., 2013; Vukadinovic-Nikolic et  
311 al., 2014]. However, we are unaware of any models that have the ability to combine  
312 different cell combinations and fluid flow to investigate the induction of early stage  
313 blood vessel formation for TE applications.

314 This work represents a significant step towards this goal. Our aim was to develop a  
315 simple synthetic pseudo-vascular network which could be recellularized to form an  
316 interconnected monolayer of ECs. A promising or successful structure was viewed as  
317 one which could demonstrate evidence of new vessel formation, sprouting outwardly  
318 from these re-endothelialized channels. The main finding of this study was the  
319 production of tubular architectures emerging from the pseudo-vasculature in response  
320 to the proangiogenic mitogen VEGF.

321 This study shows that lining of the synthetic vasculature with HDMECs was not very  
322 successful when these cells were introduced on their own. Their ability to adhere and  
323 form a continuous lining was much improved by the addition of HDFs, particularly  
324 when added to the outer layer of the synthetic channels. In summary endothelial

325 cover was relatively poor with HDMECs alone, better with the inclusion of HDFs  
326 inside the lumen together with HDMECs but best of all with HMDEC inside and  
327 HDFs outside the lumen. In other recent studies we show that fibroblasts themselves  
328 are not able to penetrate through a nanofibrous PHBV electrospun layer even after  
329 two weeks of culture [ Bye et al., 2013 and 2014].

330 Accordingly we speculate that this arrangement, HDMECs inside the channels with  
331 HDFs outside, provides the opportunity for cross talk and “reassurance” of the  
332 HDMECs by the fibroblasts as found in other studies [Dietrich and Lelkes, 2006;  
333 Kunz-Schughart et al., 2006; Hughes, 2008; Kirkpatrick et al., 2011]. It is likely that  
334 both are producing soluble and ECM factors, however this was not investigated in this  
335 particular study.

336 After the successful re-endothelialization of the synthetic channels we were keen to  
337 explore whether new vessels would sprout from these channels in response to  
338 proangiogenic stimuli; the criteria that had been originally selected as the definition  
339 of a successful system. Results showed that placing VEGF loaded collagen gels onto  
340 the scaffolds caused HDMEC outgrowth to occur from within the channels into the  
341 collagen gel showing that the engineered vasculature maintained its capacity for  
342 angiogenesis. Furthermore the HDMECs appeared to have formed perfusable tubules  
343 ( determined by connecting these nets to a syringe pump and perfusing at 40  $\mu$ l/min)  
344 within the gel. However, these tubules did not look like ‘normal’ blood vessels and  
345 were arguably closer to angiomas. There are many studies that show that VEGF on  
346 its own will direct migration of ECs but this commonly results in the formation of  
347 large and leaky vessels [Jain and Munn, 2000; Tomanek, 2002; Thurston, 2002]. It is  
348 suspected that this is the case in this particular study. It is also important to note that  
349 these results were found in around 50% of experiments, highlighting the need for

350 further optimization. However we emphasize that this is to the best of our knowledge  
351 the first demonstration of endothelial tubule formation in 3D from a synthetic  
352 vascular network. The rate of perfusion and detailed flow effects were not examined  
353 in this study (perfusion was at a fixed rate of 40  $\mu$ l/min in these experiments) but this  
354 should now be possible using these synthetic pseudo-vascular networks. Similarly we  
355 do not know what role the added fibroblasts play in the formation of these structures.  
356 In summary we previously reported the production of an EC lined synthetic pseudo-  
357 vascular network [Ortega et al., 2015]. This study has developed this work a  
358 significant step further in showing the production of perfusable tubular sprouts  
359 emanating from the HDMEC lined networks in response to the proangiogenic  
360 mitogen VEGF. This system will now lend itself to investigations of perfusion flow,  
361 the response of the cells to combinations of angiogenic mitogens and to the  
362 examination of the nature of the cross talk between the HDMECs and HDFs. It will  
363 also be important to examine the response to these cell-seeded constructs implanted in  
364 an animal model in the future. Overall these results indicate promising steps towards  
365 the development of an *in vitro* platform in which to study angiogenesis and vascular  
366 biology for a range of applications.

367

368

### 369 **Acknowledgements**

370 We thank the EPSRC funded DTC Tissue Engineering and Regenerative Medicine  
371 (EP/F505513/1) for support of LD and an EPSRC Landscape Fellowship  
372 (EP/I017801/1) program for support of IO for this research.

373

374

375

376

377 **List of Abbreviations**

378

379 HDMECs Human dermal microvascular endothelial cells

380 HDFs Human dermal fibroblasts

381 EC Endothelial cell

382 TE Tissue engineered

383 ECM Extra cellular matrix

384 VEGF Vascular endothelial growth factor

385 PHBV Poly(3-hydroxybutyrate-co-3-hydroxyvalerate)

386 DCM Dichloromethane

387 EDTA Ethylenediaminetetraacetic acid

388 H&E Hematoxylin and Eosin

389 RT Room temperature

390 PFA Paraformaldehyde

391 FFPE Formalin fixed paraffin embedded

392

393

394

395

396

397

398

399

400

401

402 **References**

403 Ashammakhi, N., et al (2008) Advancing tissue engineering by using electrospun  
404 nanofibers. *Regenerative medicine* 3: 547–74.

405 Baumert, H. et al (2007) Development of a seeded scaffold in the great omentum:  
406 Feasibility of an in vivo bioreactor for bladder tissue engineering. *European*  
407 *Urology* 52: 884-892.

408 Beachley, V., X. Wen (2010) Polymer nanofibrous structures: Fabrication,  
409 biofunctionalization, and cell interactions. *Progress in polymer science* 35: 868–  
410 892.

411 Birla, R.K. et al (2005). Myocardial engineering in vivo: Formation and  
412 characterization of contractile, vascularised three-dimensional cardiac tissue.  
413 *Tissue Engineering* 11(5/6): 803-813

414 Blackwood, K.A., et al (2008) Development of biodegradable electrospun scaffolds  
415 for dermal replacement. *Biomaterials* 29: 3091–104.

416 Bye, F.J., et al (2013) Development of bilayer and trilayer nanofibrous/microfibrous  
417 scaffolds for regenerative medicine. *Biomaterials Science* 1: 942.

418 Bye, F.J., et al (2014) Development of a Basement Membrane Substitute Incorporated  
419 Into an Electrospun Scaffold for 3D Skin Tissue Engineering. *Journal of*  
420 *Biomaterials and Tissue Engineering* 4: 686–692.

421 Carmeliet, P. (2000) Mechanisms of angiogenesis and arteriogenesis. *Nature*  
422 *Medicine* 6: 389–395.

423 Carmeliet, P., R.K. Jain (2011) Molecular mechanisms and clinical applications of  
424 angiogenesis. *Nature* 473: 298–307.

425 Correa de Sampaio, P., et al (2012) A heterogeneous in vitro three dimensional model  
426 of tumour-stroma interactions regulating sprouting angiogenesis. *PloS one* 7:  
427 30753.

428 Dew, L., S. MacNeil, et al (2015) Vascularization strategies for tissue engineers.  
429 *Regenerative medicine* 10: 211–24.

430 Dietrich, F., P. Lelkes (2006) Fine-tuning of a three-dimensional microcarrier-based  
431 angiogenesis assay for the analysis of endothelial-mesenchymal cell co-cultures  
432 in fibrin and collagen gels. *Angiogenesis* 9: 111-25.

433 Donovan, D., et al (2001) Comparison of three in vitro human “angiogenesis” assays  
434 with capillaries formed in vivo. *Angiogenesis* 4: 113–121.

435 Ellis-Behnke, R.G., et al (2006) Nano neuro knitting: peptide nanofiber scaffold for  
436 brain repair and axon regeneration with functional return of vision. *Proceedings*  
437 *of the National Academy of Sciences of the United States of America* 103:  
438 5054–9.

439 Ezaki, T., et al (2001) Time course of endothelial cell proliferation and microvascular  
440 remodeling in chronic inflammation. *The American journal of pathology* 158:  
441 2043–55.

442 Griffith, C.K., et al (2005) Diffusion limits of an in vitro thick prevascularized tissue.  
443 Tissue Engineering 11: 257–266.

444 Hughes, C. (2008) Endothelial–stromal interactions in angiogenesis. Current opinion  
445 in hematology 3:204-209.

446 Hurley, J.R., S. Balaji, et al (2010) Complex temporal regulation of capillary  
447 morphogenesis by fibroblasts. American Journal of Physiology-Cell Physiology  
448 299: 444–453.

449 Jain, R., L. Munn (2000) Leaky vessels? Call Ang1!. Nature medicine 6:131–132.

450 Kirkpatrick, C.J., S. Fuchs, et al (2011) Co-culture systems for vascularization--  
451 learning from nature. Advanced drug delivery reviews 63: 291–9.

452 Kneser, U. et al (2006). Engineering of vascularized transplantable bone tissues:  
453 Induction of axial vascularization in an osteoconductive matrix using an  
454 arteriovenous loop. Tissue Engineering 12(7): 1721-1731.

455 Kunz-Schughart, L.A., et al (2006). Potential of fibroblasts to regulate the formation  
456 of three-dimensional vessel-like structures from endothelial cells in vitro.  
457 American journal of physiology 290: 1385–98.

458 Laschke, M.W. et al (2006). Angiogenesis in tissue engineering: Breathing life into  
459 constructed tissue substitutes. Tissue Engineering 12(8): 2093-2104.

460 Mazzetti, S., et al (2004) Lycopersicon esculentum lectin: an effective and versatile  
461 endothelial marker of normal and tumoral blood vessels in the central nervous  
462 system. European journal of histochemistry 48: 423–428.

463 Moll, C., et al (2013). Tissue engineering of a human 3D in vitro tumor test system.  
464 JoVE 78.

465 Montesano, R., M. Pepper, et al (1993) Paracrine induction of angiogenesis in-vitro  
466 by swiss 3T3 fibroblasts. *Journal of cell science 105*: 1013–1024.

467 Ortega, I. et al (2015) Fabrication of biodegradable synthetic perfusable vascular  
468 networks via a combination of electrospinning and robocasting. *Biomater. Sci. 3*:  
469 592–596.

470 Santos, M.I., et al (2008) Endothelial cell colonization and angiogenic potential of  
471 combined nano- and micro-fibrous scaffolds for bone tissue engineering.  
472 *Biomaterials 29*: 4306–13.

473 Saxena, A.K. et al (2010). Esophagus tissue engineering: in situ generation of  
474 rudimentary tubular vascularized esophageal conduit using the ovine model.  
475 *Journal of Paediatric Surgery 45*: 859-864.

476 Staton, C.A., M.W.R Reed, et al (2009) A critical analysis of current in vitro and in  
477 vivo angiogenesis assays. *International Journal of Experimental Pathology 90*:  
478 195–221.

479 Thurston, G., et al (1998) Angiogenesis in mice with chronic airway inflammation:  
480 strain-dependent differences. *The American journal of pathology 153*:1099–112.

481 Thurston, G. (2002) Complementary actions of VEGF and angiopoietin-1 on blood  
482 vessel growth and leakage. *Journal of anatomy 200*:575–80.

483 Tomanek, R. (2002) *Assembly of the vasculature and its regulation*. Springer.

484 Vukadinovic-Nikolic, Z. et al (2014) Generation of Bioartificial Heart Tissue by  
485 Combining a Three-Dimensional Gel-Based Cardiac Construct with  
486 Decellularized Small Intestinal Submucosa. *Tissue engineering part a 20*: 799–  
487 809.

488

489

490 **Figure Legends**

491

492 *Figure 1. Appearance of pseudovascular net and diagram of its perfusion. A shows*  
493 *the appearance of one of the pseudovascular nets which had the overall dimensions of*  
494 *2cm x 4cm. B shows that the pseudovascular net is designed to be cannulated with a*  
495 *needle and perfused. For detailed description of the production of the pseudovascular*  
496 *net, please see Ortega et al, 2015.*

497

498 *Figure 2. Immunohistochemical staining of human dermal fibroblasts and human*  
499 *dermal microvascular endothelial cells on the surfaces of the pseudovascular net*

500 **A – C.** FFPE cross sections through a vascular scaffold where HDMECs were seeded  
501 on the inside of the scaffold lumen, stained with H&E and imaged 4, 10 and 20 ×  
502 magnification respectively. (For a detailed description of the production of these  
503 scaffolds please see Ortega et al 2015 ).Scale bar shows 100 μM. **D – F.** As in A – C,  
504 but showing scaffolds with HDMECs and HDFs seeded within the scaffold lumen. **G**  
505 **– I.** As in A – C but with HDMECs seeded inside and HDFs seeded outside the  
506 vascular scaffold.

507

508 *Figure 3. Confluent endothelial monolayers within the pseudovascular net's channels*  
509 *are formed with support of human dermal fibroblasts.*

510 Pseudovascular nets were sectioned parallel to the lower surface of the channel  
511 (indicated by cartoon above images) and both surfaces were immunostained with anti-  
512 CD31 (HDMECs, red) and DAPI (nuclei, blue) before images were taken by confocal  
513 microscopy and z-stacked images compressed to generate an image of the whole  
514 surface. Scale bar = 100 μM. **A and B.** Upper and lower inner surfaces seeded with

515 HDMECs alone. **C and D.** Upper and lower inner surfaces seeded with HDMECs and  
516 HDFs seeded inside the channel of the vascular net. **E and F.** Upper and lower inner  
517 surfaces seeded with HDMECs inside the channel and HDFs seeded outside the  
518 channel of the pseudovascular net.

519

520 *Figure 4. Endothelial cells on the inside surface of the pseudovascular net have VE-*  
521 *Cadherin positive adherens junctions.* Pseudovascular nets were seeded with  
522 HDMECs inside the channel and HDFs outside the channels and sectioned as  
523 described in Fig 3. Sections were immunostained with anti-VE-Cadherin (red) and  
524 DAPI (nuclei, blue) before images were taken by confocal microscopy. Z-stacks of  
525 images were compressed to generate an image of the whole surface. **A** –Scale bar =  
526 100  $\mu$ M. **B** - Scale bar = 20  $\mu$ M.

527

528 *Figure 5. Human dermal endothelial cells exit the pseudovascular net to form a*  
529 *perfusible network within VEGFA loaded collagen-I gels.* **A.** Diagram showing the  
530 process of making holes in a pseudovascular net that has been pre-seeded internally  
531 with HDMECs, and externally with HDFs. After 7 days culture, holes are made on the  
532 inner side of the net's artificial vascular channels facing into the hexagonal well using  
533 a 21 gauge needle. The hexagonal area is then filled with collagen-I containing  
534 VEGFA and allowed to set before submerging in medium for a further 7 days to allow  
535 growth of cells from the net into the collagen gel. **B.** 3D confocal projection of CD31  
536 positive structures within the collagen-I gel from the centre of the hexagonal well. **C.**  
537 Confocal images of nuclei (blue), Lectin-FITC (green) and CD31 (red) and merged  
538 image of all three channels of the collagen-I gel within the centre of the hexagonal  
539 well after perfusion of the pseudovascular net with Lectin-FITC. Scale bar is 100  $\mu$ m.

Figure 1




Figure 2




Figure 3










Figure 4





Figure 5

